#South Korea #Seoul #Seegene #CURECA #PCR Automation

Seegene Launches CURECA(TM): A New Era in PCR Automation

In the evolving landscape of molecular diagnostics, Seegene Inc. has taken a monumental step ahead with its CURECA(TM) technology. Unveiled during the ESCMID Global 2025 conference in Vienna, Austria, this innovative system has stirred considerable excitement among the scientific community, marking a significant leap towards comprehensive PCR automation. With its modular design, CURECA(TM) aims to automate sample preparation processes across various diagnostic fields, including clinical chemistry and immunological testing.

A Closer Look at CURECA(TM)

By utilizing cutting-edge technology, CURECA(TM) promises to revolutionize the way we conduct polymerase chain reaction (PCR) diagnostics. The system is built to manage the entire diagnostic workflow, from handling primary samples like stool, urine, and blood to performing PCR after sample insertion seamlessly. This comprehensive automation minimizes human error, enhances testing efficiency, and reduces processing times during laboratory operations.

Young-Seag Baeg, Seegene's Head of Strategy and Planning, highlighted the significant advantage of CURECA(TM) in streamlining diagnostic processes, stating that it holds high promise in freeing laboratories from traditional manual procedures susceptible to errors. The enthusiasm surrounding the product at ESCMID 2025, where over 2,300 attendees explored its conceptual video, reinforced its potential to transform laboratory workflows globally.

Experts Weigh In

Experts attending the conference widely recognized CURECA(TM) as a groundbreaking advancement in PCR testing automation. One attendee remarked, "The high level of automation has the potential to eliminate human errors common in traditional manual testing. With CURECA(TM), efficient testing capability will increase without the constraints of time or labor."

Another expert added, "The automation of sample preparation is a real paradigm shift. The level of integration in CURECA(TM) distinguishes it from existing solutions, and I am eager for its commercial launch."

There is a collective anticipation in the industry as stakeholders express eagerness for CURECA(TM) to be accessible to smaller and mid-sized laboratories. Many view it as a key player in the diagnostics market, further enhanced by potential collaborations set to be discussed at the upcoming ADLM 2025 exhibition in Chicago.

Customizable Automation for Future Laboratories

CURECA(TM) features a customizable Preprocessing System (CPS), designed specifically to facilitate integration with various laboratory settings. The modular CPS refines the processing of primary sample tubes, ensuring streamlined workflows in molecular diagnostics and beyond.

The concept of customizable automation resonated with numerous delegates at the conference, with many expressing that the CPS could revolutionize in vitro diagnostics by transcending limitations faced by manual techniques reliant on skilled personnel.

"The introduction of CPS will shorten turnaround times significantly, particularly for sexually transmitted infections (STI) samples which often require cumbersome manual handling of multiple tubes," stated one laboratory director from Spain. This module’s ability to enhance laboratory efficiency showcases its transformative potential.

Discussing Flexibility and Space Optimization

The overall architecture of CURECA(TM) is not only modular but also optimized for varying laboratory spaces. This flexibility is crucial for laboratories aiming to maximize operational effectiveness, allowing them to tailor systems to specific needs effectively.

Participants at ESCMID shared their insights on the system's adaptability:

• - "The ability to configure the system around specific spatial and operational requirements is an exciting and promising development."
• - "We expect this flexibility will enable workflows that yield high-quality results with minimal reliance on standardized laboratory configurations."

Conclusion: A Promising Future for Diagnostics

Jong-Yoon Chun, the CEO of Seegene, expressed optimism about the extensive global response to the CURECA(TM) concept. He noted, "Our vision reflects a strong demand for next-generation diagnostic solutions in the molecular field. We are confident that CURECA(TM) has the potential to catalyze meaningful change in global PCR diagnostics."

As the anticipation builds toward the commercial release of CURECA(TM) in July, the biotechnology community remains on the edge of their seats, eager to witness its impact on the future of health diagnostics.

For more information about Seegene and the innovative CURECA(TM) system, visit Seegene.com.